Lung Tumors Unit
What does the Unit treat?
The Lung Tumors Unit of HM CIOCC is a national reference, specialized in the treatment of non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). This distinction is crucial, as NSCLC, the most common type of lung cancer, and SCLC, which is faster-growing and more aggressive, require very different therapeutic approaches. Our expertise ranges from the most innovative therapies for NSCLC, such as immunotherapy and targeted therapies, to the most effective chemotherapy regimens for SCLC.
At HM Hospitals (CIOCC), the Lung Tumors Unit focuses on:
- Development of clinical trials focused on combinations of new immunotherapies for non-small cell lung carcinoma.
- Specific targeted treatments for patients with non-small cell lung carcinoma.
- Treatments for patients with small cell lung carcinoma.
Related Diseases
- Pulmonary Nodule.
- Lung Cancer.
Who is this Unit for?
The Lung Tumors Unit is aimed at:
- Patients with non-small cell and small cell lung carcinoma.
- Patients seeking to participate in clinical trials with immunotherapies and targeted treatments.
- Family members and caregivers seeking information and support for their loved ones with lung cancer.
- Healthcare professionals who wish to refer patients for specialized lung tumor evaluation and treatment.
How do we approach it at HM Hospitals?
Surgery
We aim to remove as much of the tumor as possible, preserving the function of the reproductive organs to the maximum extent.
Chemotherapy
We use state-of-the-art medications to reach and destroy cancer cells that may be present anywhere in the body.
Radiotherapy
We direct high-energy beams to destroy cancer cells, minimizing damage to surrounding healthy tissues.
Targeted therapies
They act on specific molecular targets of cancer cells, selectively disrupting their growth and spread.
Immunotherapy
Through drugs, we stimulate the patient’s immune system to naturally recognize and attack cancer cells.